tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SVRA Stock Latest News

Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
RatingsSavara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
9d ago
SVRA
Savara Highlights Autoimmune PAP Burden in Updated Presentation
PremiumCompany Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
10d ago
8K
SVRA
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
PremiumRatings
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
27d ago
SVRA
Savara price target raised to $10 from $8 at H.C. Wainwright
PremiumThe Fly
Savara price target raised to $10 from $8 at H.C. Wainwright
27d ago
SVRA
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
PremiumRatings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
28d ago
SVRA
Savara resubmits Molbreevi BLA to the FDA
PremiumThe FlySavara resubmits Molbreevi BLA to the FDA
28d ago
SVRA
Savara announces EPO intention to grant Molbreevi patent application
Premium
The Fly
Savara announces EPO intention to grant Molbreevi patent application
1M ago
SVRA
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
Premium
Ratings
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
1M ago
SVRA
Savara rumor highlighted in Betaville blog
PremiumThe Fly
Savara rumor highlighted in Betaville blog
2M ago
SVRA
Savara issues patent for Molbreevi from European Patent Office
PremiumThe Fly
Savara issues patent for Molbreevi from European Patent Office
2M ago
SVRA
Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
PremiumRatings
Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
2M ago
SVRA
Savara Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Savara Inc. Reports Q3 2025 Financial Results
2M ago
SVRA
Savara price target raised to $9 from $8 at Oppenheimer
PremiumThe FlySavara price target raised to $9 from $8 at Oppenheimer
2M ago
SVRA
Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
Premium
Ratings
Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
2M ago
SVRA
Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential
Premium
Ratings
Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential
2M ago
SVRA
Savara price target lowered to $10 from $11 at Citizens JMP
PremiumThe Fly
Savara price target lowered to $10 from $11 at Citizens JMP
2M ago
SVRA
Savara reports Q3 EPS (14c), consensus (13c)
PremiumThe Fly
Savara reports Q3 EPS (14c), consensus (13c)
2M ago
SVRA
Savara Hit with Class Action Over Molbreevi Misrepresentations
PremiumMarket News
Savara Hit with Class Action Over Molbreevi Misrepresentations
3M ago
SVRA
Savara Announces $130 Million Public Offering
PremiumCompany Announcements
Savara Announces $130 Million Public Offering
3M ago
8K
SVRA
Savara 23.81M share Spot Secondary priced at $4.20
PremiumThe FlySavara 23.81M share Spot Secondary priced at $4.20
3M ago
SVRA
Savara Announces $75M Royalty Funding Agreement
Premium
Company Announcements
Savara Announces $75M Royalty Funding Agreement
3M ago
8K
SVRA
Savara announces offering of common stock and warrants, no amount given
Premium
The Fly
Savara announces offering of common stock and warrants, no amount given
3M ago
SVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >